-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US53271X1081 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.76 |
|---|---|
| Market Cap | 8M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LIMN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026